Search Results
Feb 23, 2026, 08:06 ET Hach wprowadza na rynek analizator fosforanów NP6000sc - nowy standard niezawodności oraz prostsza eksploatacja zapewniają niezawodne pomiary pozwalając kontrolować poprawność procesu technologicznego pod kątem spełniania norm prawnych.
analizatora fosforanów NP6000sc zwiększa pewność kontroli procesu technologicznego dzięki ciągłym, precyzyjnym pomiarom w trzech zakresach (0,015-75 mg/L), umożliwiając uzyskanie dokładności wyniku klasy laboratoryjnej bezpośrednio w układzie technologicznym.NP6000sc wychodzi naprzeciw wyzwaniom
More news about: Hach
Feb 23, 2026, 08:06 ET Hach stellt den Phosphat-Analysator NP6000sc vor, der neue Maßstäbe in Sachen Zuverlässigkeit setzt und die Einhaltung von Vorschriften für Wasseraufbereitungsanlagen vereinfacht
NP6000sc Phosphat-Analysators sorgt für mehr Vertrauen in die Prozessleistung durch kontinuierliche, präzise Messungen in drei Bereichen (0,015–75 mg/l), sodass Bediener direkt im Prozess eine Genauigkeit auf Laborqualität erreichen können.Der NP6000sc löst dieses Problem direkt durch ein innovatives
More news about: Hach
Feb 23, 2026, 08:06 ET Hach onthult NP6000sc Phosphate Analyser en herdefinieert betrouwbaarheid en vereenvoudigt compliance voor waterzuiveringsinstallaties
van de NP6000sc Phosphate Analyser zorgt voor meer vertrouwen in procesprestaties door continue en nauwkeurige metingen over drie bereiken (0,015–75 mg/L), waardoor operators laboratoriumwaardige nauwkeurigheid direct in het proces kunnen bereiken.De NP6000sc pakt dit direct aan via een innovatief
More news about: Hach
Feb 23, 2026, 08:06 ET Hach presenta NP6000sc, l'analizzatore di fosfati che ridefinisce l'affidabilità e semplifica la conformità normativa per gli impianti di trattamento delle acque
fosfati NP6000sc introduce una maggiore affidabilità nelle prestazioni di processo grazie a misurazioni continue e precise su tre intervalli (0,015-75 mg/L). In questo modo, gli operatori possono ottenere direttamente nel processo un livello di precisione paragonabile a quello di laboratorio.L'NP6000sc
More news about: Hach
Feb 23, 2026, 08:06 ET Hach presenta el analizador de fosfatos NP6000sc
analizador de fosfatos NP6000sc ofrece mayor confianza en el rendimiento del proceso mediante mediciones continuas y precisas en tres rangos (0,015–75 mg/L), lo que permite a los operadores lograr una precisión de laboratorio directamente en el proceso.El NP6000sc aborda este problema directamente
More news about: Hach
Feb 23, 2026, 08:06 ET Hach dévoile l'analyseur d'ortho-phosphates NP6000sc, redéfinissant la fiabilité et simplifiant la conformité pour les installations de traitement de l'eau.
l'analyseur de phosphate NP6000sc renforce la confiance dans les performances du procédé grâce à une mesure continue et précise sur trois gammes (0,015–75 mg/L), permettant aux opérateurs d'atteindre une précision de niveau laboratoire directement sur le procédé.Le NP6000sc répond à ces enjeux grâce à
More news about: Hach
Feb 23, 2026, 08:00 ET Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1
More news about: Genprex, Inc.
Feb 23, 2026, 08:00 ET Omalizumab Triggers T Cell Modification, Increasing the Reaction Thresholds to Common Food Allergens
treatments reduced IL-4⁺peanut-reactive and IL-4⁺CD4⁺T cells; Fcepsilon;RI⁺mDCs/pDCs decreased only in the omalizumab plus placebo OIT group, while OX40L⁺mDCs/pDCs decreased only in the omalizumab-facilitated OIT group. Researchers found that, after Stage 1, participants passing the 600 mg peanut challenge
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 23, 2026, 08:00 ET ITF Therapeutics LLC Announces Multiple Data Presentations at 2026 MDA Clinical and Scientific Conference
Hospital of Philadelphia Poster number: 50S Title: Characterizing Platelet Count Reductions Below 75 × 109/L in Patients with Duchenne Muscular Dystrophy Treated with Givinostat from the Phase 3 EPIDYS Trial and LTSE Study Presenter: Paolo
More news about: ITF Therapeutics LLC
Feb 23, 2026, 07:56 ET Veterans United Home Loans Adds 19th Sergeant Major of the Marine Corps Troy Black to Military Advisory Team
Veterans United's Military Advisory Team is unique within the mortgage industry.Black succeeds Ronald L. Green, the 18th Sergeant Major of the Marine Corps, who has served as a valued advisor to the company. Black's hiring further strengthens a one-of-a-kind
More news about: Veterans United Home Loans
Feb 23, 2026, 07:27 ET PAN GLOBAL COMMENCES 2026 DRILL PROGRAM AT ESCACENA PROJECT, SPAIN
(method Au-ICP22).As an additional quality control measure, approximately 10% of the samples were also subjected to check analysis using method ME-MS41L, involving aqua regia digestion followed by analysis via ICP-MS and ICP-AES. These check assays were used to verify analytical accuracy and consistency
More news about: Pan Global Resources Inc.
Feb 23, 2026, 07:27 ET PAN GLOBAL BEGINNT BOHRPROGRAMM 2026 IM PROJEKT ESCACENA, SPANIEN
auf Gold analysiert wurden.Als zusätzliche Qualitätskontrollmaßnahme wurden etwa 10 % der Proben einer Kontrollanalyse nach der Methode ME-MS41L unterzogen, die eine Aufschluss mit Königswasser und anschließende Analyse mittels ICP-MS und ICP-AES umfasst. Diese Kontrollanalysen dienten der Überprüfung
More news about: Pan Global Resources Inc.
Feb 23, 2026, 07:27 ET PAN GLOBAL COMMENCES 2026 DRILL PROGRAM AT ESCACENA PROJECT, SPAIN
(method Au-ICP22).As an additional quality control measure, approximately 10% of the samples were also subjected to check analysis using method ME-MS41L, involving aqua regia digestion followed by analysis via ICP-MS and ICP-AES. These check assays were used to verify analytical accuracy and consistency
More news about: Pan Global Resources Inc.
Feb 23, 2026, 07:27 ET PAN GLOBAL LANCE LE PROGRAMME DE FORAGE 2026 SUR LE PROJET ESCACENA, EN ESPAGNE
mesure supplémentaire de contrôle de la qualité, environ 10 % des échantillons ont également été soumis à une analyse de contrôle selon la méthode ME-MS41L, impliquant une digestion à l'eau régale suivie d'une analyse par ICP-MS et ICP-AES. Ces essais de contrôle ont été utilisés pour vérifier la précision
More news about: Pan Global Resources Inc.
Feb 23, 2026, 07:00 ET FDA Approves VUEWAY® (gadopiclenol) Solution for Injection, Intravenous Use, for Use in Neonates and Infants
Contrast Agent for MRI of the CNS and Body. Invest Radiol 2024; 59(2):124-130.7 Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity. J Magn Reson Imaging
More news about: Bracco Group
Feb 22, 2026, 19:10 ET CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
(ESCC)."About SugemalimabThe anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody,
More news about: CStone Pharmaceuticals
Feb 22, 2026, 17:36 ET Franco-Nevada Announces A$220 Million Financing Package with Minerals 260 for the Bullabulling Gold Project
Hay Street, West Perth WA 6005. Franco-Nevada's head and registered office is located at 2000-199 Bay Street, Commerce Court West, Toronto, Ontario, M5L 1G9.Information relating to Bullabulling contained in this news release has been provided by Minerals 260. All Mineral Resource estimates are reported
More news about: Franco-Nevada Corporation
Feb 22, 2026, 14:05 ET Oracle Corporation (ORCL) Investors: April 6, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
1:26-cv-00127-JLH, was filed on February 3, 2026, in the United States District Court for the District of Delaware and is pending before the Honorable Jennifer L. Hall.
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 21, 2026, 08:00 ET TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
__________________________1 Peyrin-Biroulet L, et al. Efficacy and safety of guselkumab for ulcerative colitis through week 140 of the QUASAR long-term extension study. Poster presentation (DOP104)
More news about: Johnson & Johnson
Feb 21, 2026, 01:57 ET 私補市場2026新趨勢｜補習平台分享上門補習價錢2026及揀補習導師三大常見中伏位及貼士
影響上門補習收費的三大因素1. 老師資歷補習老師的教育背景及教學經驗是決定收費的關鍵因素之一。一般而言，補習老師的資歷越高，收費也會越高。例如：如聘請 DSE 成績達 L5 至 L5** 的大學生為中三學生補習，視乎不同學科時薪約為 $220-$320；如聘請 DSE 成績達 L5 至 L5** 的全職補習導師為中三學生補習，視乎不同學科時薪約為 $300-$450；如想尋求現職中學教師進行私補，時薪需至少 $500-$600起。大部分上門補習老師為大學生，他們多數將補習視為兼職，因此收費相對較低。例如，小六學生的上門補習收費大約為
More news about: Tutor Circle Limited
Feb 20, 2026, 22:00 ET 私補市場2026新趨勢｜補習平台分享上門補習價錢2026及揀補習導師三大常見中伏位及貼士
影響上門補習收費的三大因素1. 老師資歷補習老師的教育背景及教學經驗是決定收費的關鍵因素之一。一般而言，補習老師的資歷越高，收費也會越高。例如：如聘請 DSE 成績達 L5 至 L5** 的大學生為中三學生補習，視乎不同學科時薪約為 $220-$320；如聘請 DSE 成績達 L5 至 L5** 的全職補習導師為中三學生補習，視乎不同學科時薪約為 $300-$450；如想尋求現職中學教師進行私補，時薪需至少 $500-$600起。大部分上門補習老師為大學生，他們多數將補習視為兼職，因此收費相對較低。例如，小六學生的上門補習收費大約為
More news about: Tutor Circle Limited
Feb 20, 2026, 10:57 ET Genshaft, Greenbaum Gift Names Taneja Tower Operating Suite at Tampa General Hospital
academic health system, is a 1,530-bed not-for-profit network of hospital and outpatient services spanning across Florida. As the only center for Level l trauma and comprehensive burn care center serving 23 counties, Tampa General delivers world-class care. The system's hospitals include Tampa General Hospital,
More news about: Tampa General Hospital
Feb 20, 2026, 10:10 ET Manhattan Review Releases Fourth Edition of GRE Prep Book Series
https://www.manhattanreview.com (Manhattan Review's official website).Media Contact:Karen L MillerManhattan Review, Inc.2 Park Ave Ste 2010New York, NY 10016Phone: (212) 316-2000Email:
More news about: Manhattan Review, Inc.
Feb 20, 2026, 09:10 ET INVESTOR DEADLINE: NuScale Power Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ENTRA1 was sufficiently experienced to own and operate the energy generation facilities contemplated by the TVA agreement. NuScale's CEO, defendant John L. Hopkins, further revealed during the call that the agreement between ENTRA1 and TVA contemplated as many as 72 NPMs, meaning NuScale's milestone payments
More news about: Robbins Geller Rudman & Dowd LLP
Feb 20, 2026, 09:03 ET SCRUBBING BUBBLES® EASY CLEAN PRODUCT LINE WINS 2026 PRODUCT OF THE YEAR USA AWARD
half of the Fortune 500 companies in 100 countries.NielsenIQ Scantrack Data, Total U.S. xAOC, Bath Cleaner Category, Sales $ Volume L52 WE 1.26.26vs. leading all-purpose cleaner on limescale
More news about: Scrubbing Bubbles